Get started
DR.REDDYS LABORATORIES LTD.DR.REDDYS LABORATORIES LTD.DR.REDDYS LABORATORIES LTD.

DR.REDDYS LABORATORIES LTD.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

DRREDDY trade ideas

REDDYS LABS Dr. Reddy's Laboratories Ltd is a leading India-based pharamceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations. Stock is trading at 3.80 times its book value and maintaining a healthy dividend payout of 21.6% Zero pledging by promoters , Debt to Equity ratio of 0.17 Good Fundamentals , Stock formed Ascending triangle pattern in chart , breakout above 4465 will give good up move as mentioned
NSE:DRREDDYLong
by madhu2811
DRREDDY's is +25% YTD as Double-Digit Gains ContinueDr Reddy's Laboratories (NSE: DRREDDY)(NYSE: RDY) is a > MUN:10B pharma powerhouse based in India with a fast-expanding global footprint. This innovative juggernaut for pharma and biotech has witnessed a highly bullish price action uptrend YTD, with nearly 25% gains registered for its NSE ticker as of market close on Friday, situating share price some 5% above analyst forecasts. After the company released a comprehensive year-end report in recent weeks, it looks like solid fundamentals are underlying this impressive growth. Here are a couple core reasons why I think DRREDDY remains a strong investment opportunity over coming quarters: -In the past month Dr Reddy's has passed two US FDA inspections at three different plants in India. Particularly when looking at a pharma company, adherence to regulatory and quality standards is a make or break. The fact that Dr Reddy's is blazing through FDA inspections with zero observations is a strong sign that the company is upholding the global gold standard when it comes to regulatory/safety adherence, as well as giving a green light for the roll-out of new products. -Expansion into the global generics market will serve as an engine for growth moving forward. The company unveiled its foray into the generics business through the introduction of an innovative business unit called RGenX. Focusing on acute segment products, Dr. Reddy's aims to revolutionize the market by employing a unique model driven by channel partners, empowering retailers to distribute medicines without specific healthcare professional recommendations. This recent bold move, coupled with Dr. Reddy's consistent strides in penetrating the highly significant Indian market, positions the company exceptionally well to thrive amidst the soaring growth of the Indian pharmaceuticals market. Astute investors seeking promising ventures should take heed of this transformative development, as Dr. Reddy's emergence in the generics arena presents a lucrative opportunity for substantial rewards. -ESG values represent a core pillar of DRREDDY's business model, making this a rare investment opportunity in the pharma sector that you can feel good about. A look at the company's year end report evidences the length to which the company has committed itself to ambitious inclusivity and diversity goals by 2030 for its senior leadership, as well as a raft of initiatives intended to bolster environmental sustainability and community building. Above all, the company strives to reach over 1.5B people by 2030, which will represent >10% of the global population! As market segment increases, investors can expect portfolio gains to flow in as well, creating a win-win situation. Lastly, the company has been outperforming both market index baselines and is currently trading above its own MA ribbon. Notwithstanding a dip in share price caused by market jitters in May after missing EPS forecasts for FY Q4, share price has come roaring back, leaving analysts' forecasts in the dust. We're just beginning to witness the bullish potential of this pharma multibagger, if its not already on your watchlist or in your portfolio, I for one would take a second look.
NSE:DRREDDYLong
by BiotechBrandon
$DRREDDY is in the Midst of a Full-Blown Bullish RecoveryDr. Reddy's Laboratories is a leading pharmaceutical and biotechnology company that has established a robust business model, enabling it to achieve sectoral domination in the pharma/biotech industry. With a history spanning several decades, Dr. Reddy's has consistently focused on innovation, research, and development to create a diverse portfolio of high-quality generic drugs, biosimilars, and proprietary pharmaceuticals. The company's business model revolves around a multi-faceted approach that encompasses vertical integration, strategic partnerships, and global market penetration. Dr. Reddy's Laboratories has strategically expanded its operations across geographies, including the United States, Europe, India, and emerging markets, thus securing a strong foothold in various regions. This global presence enables the company to tap into diverse patient populations and healthcare systems, ensuring widespread accessibility to their products. Dr. Reddy's commitment to quality, affordability, and efficacy has propelled its growth and led to sectoral domination in the pharma/biotech industry. The company's extensive research capabilities, coupled with a strong regulatory track record, enable the efficient development and commercialization of complex generics and biosimilars. Furthermore, strategic partnerships and collaborations with global pharmaceutical companies contribute to its continued success. Earlier in Q2, DRREDDY released financials that were largely positive in terms of revenue growth and global expansion yet slightly underperformed EPS forecasts. This caused a bearish market reaction that led to a ~10% drop-off in share price on May 10th. That said, this downturn in investor sentiment has been short-lived. In recent weeks, share price has recovered nearly 7% from a local minimum posted on May 19th while technical indicators are bullish. As shown in the chart, MACD is positive, RSI in fairly-valued territory, and DRREDDY is trading about multiple MA lines. The takeaway from this analysis is that Dr Reddy's is fast making up lost ground from its mid-Q2 dip. Analyst predict up to 27% upside for DRREDDY share price from it current value, meaning we can expect the gains to continue. Given last week's announcement that the company successfully completed Phase I trials for a new anti-rheumatic drug candidate, fundamental catalysts support this forecast. This is not financial advice, but I expect ongoing recovery of DRREDDY share price, in line with analyst price targets and a corresponding BUY rating.
NSE:DRREDDYLong
by dave_kellr85
DRREDDY--Strong Support @4200 levels.Observations:: ------>> we have detected that the stock is in the form of Head and Shoulders Pattern. ------>> If the demand zone @4600 acts as resistance, will go for sell below left shoulder rejection level, for the target of 4400 and 4200 levels. ------>> We have a great support @4200 , indicating a bullish gap + continuation to upside. ------>> look for buying in these levels to go for the target of upside bearish gap, and 5000 levels.
NSE:DRREDDY
by IIT-Trader
$RDY is Undervalued and Trending Up After Q4 Earnings DipDr Reddy's (NASDAQ: RDY) is an India-based pharma company that is one of the most dynamic companies in the industry. The company is up nearly +7% YTD, though share price dipped last week after the release of Q4/FY2023 financials due to base business growth lagging behind forecasts. However, I see this recent decrease as a prime window of opportunity to establish or augment a position in RDY given the broader picture their financials paint. Though RDY's EPS slightly missed Zacks Consensus estimate by $0.01, FY2023 EPS was $3.30 compared to $1.72 the year prior, which indicates substantial YoY growth. Furthermore, revenue was up 15% compared to last year, evidencing a strong and growing cash flow for this global pharma giant. Even more promising was the 36% YoY growth Dr Reddys' saw in the category of North American generics, a region that constituted the plurality (40%) of net global sales. These robust growth figures were buoyed by record sales in FY2023 powered by numerous new product launches (including 12 news ANDAs with the US FDA) as RDY engages additional pharma verticals. Likewise, cashflow and cash and hand remains strong, showing that this company has the underlying capital needed to continue funding R&D and global expansion efforts. RDY's fiscal picture for the entirety of FY2023 looks overall strong and very promising for the short and intermediate-term future. Looking at the chart, one can clearly see the dip caused by some bearish sentiment after the release of financials on May 10th. However, both MACD and Momentum indicators are trending positive, suggesting a recovery in share price ahead. Meanwhile the stock maintains an average analyst PT of $61 for 10% upside from its current $55.30; given that share price had already exceeded this consensus estimate before the release of financials, this pullback can be viewed as a temporary recalibration that lays the groundwork for sustained gains moving forward. RDY is a solid pharma midcap with a highly profitable bottom line, significant innovative capital, an ambitious R&D pipeline and a fast-expanding global footprint. Looking forward to see where things go from here, but for now I'm LT bullish on RDY.
NYSE:RDYLong
by EagleEyeAnalytics